Loading clinical trials...
Loading clinical trials...
GnRH Agonist Triggering Supplemented With Hcg in Women With Poor Ovarian
During the last decades, owing to the growing tendency of women to delay childbearing plans because of career and personal priorities, fertility specialists today are seeing more and more women with poor ovarian reserve and with poor ovarian response Controlled ovarian hyperstimulation (COH) is considered a important factor in the success of in vitro fertilization-embryo transfer (IVF-ET), enabling the recruitment of multiple oocytes and, thereby, resulting in more than one embryo. However, owing to the extreme variability in ovarian response to COH, in a subgroup of patients with poor ovarian response, this method may yield a very small number of follicles After succeeding in maximal recruitment of the follicles, the triggering of ovulation is extremely important in order to achieve, as many as, mature oocytes. Several studies have reported retrieval of more mature oocytes after GnRH agonist triggering compared to the number of oocytes retrieved after hCG. Among the possible advantages of GnRH agonist for final oocyte maturation is the simultaneous induction of an FSH surge. The role of the natural mid-cycle FSH surge is not fully clear. FSH was reported to induce LH receptor formation in luteinizing granulosa cells, and to promote oocyte nuclear maturation and cumulus expansion . Another method described to trigger ovulation is the "Dual triggering"- GnRH agonist 40 h prior to ovum pickup and hCG added 6 h after the first trigger. The dual triggering was described as the treatment in cases with recurrent empty follicles. The aim of the present study is to evaluate three different methods of ovulation triggering in women with poor ovarian response
Inclusion criteria: * Women with low ovarian response according to the Bologna criteria, undergoing IVF treatments for this cause. Exclusion criteria: * Women with good ovarian response. * Women with low ovarian response who are carriers of fragile X
Age
18 - 45 years
Sex
FEMALE
Healthy Volunteers
Yes
Sheba medical center
Ramat Gan, Israel
Start Date
January 1, 2014
Primary Completion Date
July 1, 2015
Completion Date
July 1, 2015
Last Updated
May 22, 2014
60
ESTIMATED participants
Ovitrel
DRUG
Decapeptyl
DRUG
Lead Sponsor
Sheba Medical Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions